HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA reform conference

This article was originally published in The Rose Sheet

Executive Summary

FDA reform conference: Vote on FDA reform legislation (S 830/HR 1411) report was slated to take place as of Nov. 9. The White House has said it is considering a veto of the conference report because of disagreements over a number of provisions in the legislation. The conference got under way Nov. 5, following several weeks of preconference staff meetings. House conferees include Reps. Tom Bliley (R-Va.), Michael Bilirakis (R-Fla.), Jim Greenwood (R-Penn.), Joe Barton (R-Tex.), Richard Burr (R-N.C.), Ed Whitfield (R-Ky.), John Dingell (D-Mich.), Henry Waxman (D-Calif.), Sherrod Brown (D-Ohio) and Ron Klink (D-Penn.). Senate conferees include James Jeffords (R-Vt.), Dan Coats (R-Ind.), Judd Gregg (R-N.H.), Bill Frist (R-Tenn.), Mike Dewine (R-Ohio), Edward Kennedy (D-Mass.), Christopher Dodd (D-Conn.), Tom Harkin (D-Iowa) and Barbara Mikulski (D-Md.)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel